Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
61.7M
-
Number of holders
-
135
-
Total 13F shares, excl. options
-
50.3M
-
Shares change
-
+1.7M
-
Total reported value, excl. options
-
$1.19B
-
Value change
-
+$11.4M
-
Put/Call ratio
-
0.37
-
Number of buys
-
71
-
Number of sells
-
-68
-
Price
-
$23.68
Significant Holders of Protagonist Therapeutics, Inc - COMMON STOCK (PTGX) as of Q1 2022
179 filings reported holding PTGX - Protagonist Therapeutics, Inc - COMMON STOCK as of Q1 2022.
Protagonist Therapeutics, Inc - COMMON STOCK (PTGX) has 135 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.3M shares
of 61.7M outstanding shares and own 81.53% of the company stock.
Largest 10 shareholders include FMR LLC (7.13M shares), RTW INVESTMENTS, LP (4.79M shares), BVF INC/IL (4.18M shares), STATE STREET CORP (3.26M shares), BlackRock Inc. (3.25M shares), Point72 Asset Management, L.P. (2.92M shares), JOHNSON & JOHNSON (2.45M shares), VANGUARD GROUP INC (2.33M shares), MORGAN STANLEY (1.34M shares), and FARALLON CAPITAL MANAGEMENT LLC (1.13M shares).
This table shows the top 135 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.